Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints

Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met its dual primary endpoints of overall survival/OS and progression-free survival/PFS in patients with advanced or recurrent endometrial cancer. The investigational TROP2-directed antibody-drug conjugate, developed in collaboration with Kelun-Biotech, is the first global Phase 3 trial to show statistically significant improvements in OS and PFS compared to standard chemotherapy in this patient population.

The pre-specified interim analysis demonstrated clinically meaningful efficacy against the physician’s choice of treatment (doxorubicin or paclitaxel) for individuals whose disease progressed following platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. The trial also achieved its key secondary endpoint of objective response rate, maintaining a safety profile consistent with prior sac-TMT studies with no new safety signals.

This milestone represents the first positive Phase 3 data from Merck & Co. Inc.’s (NYSE:MRK)  expansive TroFuse clinical development program. The ongoing program encompasses 17 global Phase 3 trials across multiple tumor types (including bladder, breast, cervical, and non-small cell lung cancers) and aims to establish the therapy as a cornerstone treatment in both early and late-stage disease settings.

Merck & Co. Inc. (NYSE:MRK) is a healthcare firm that provides health solutions, vaccines, biologic therapies, animal health, and more. It operates in pharmaceuticals, animal health, and other segments.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1